East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL)
Keunchil Park, Joo-Hang Kim, Eun Kyung Cho, Jin-Hyoung Kang, Jin-Yuan Shih, Annamaria Hayden Zimmermann, Pablo Lee, Ekaterine Alexandris, Tarun Puri, Mauro Orlando
Cancer Res Treat. 2016;48(4):1177-1186. Published online 2016 Feb 22 DOI: https://doi.org/10.4143/crt.2015.401
Citations to this article as recorded by 
Efficacy and outcomes of ramucirumab and docetaxel in patients with metastatic non-small cell lung cancer after disease progression on immune checkpoint inhibitor therapy: Results of a monocentric, retrospective analysis
Samuel A. Kareff, Kunal Gawri, Khadeja Khan, Deukwoo Kwon, Estelamari Rodriguez, Gilberto de Lima Lopes, Richa Dawar
Frontiers in Oncology.2023;[Epub] CrossRef
Clinical Trial and Real-World Outcomes of Patients With Metastatic NSCLC in the Post-Platinum–Based Chemotherapy Failure Setting
Yu Yang Soon, Wesley Furnback, Jin Kim, Po-Ya Chuang, Gordon Chavez, Christina Proescholdt, Cloe Ying Chee Koh
JTO Clinical and Research Reports.2023; 4(11): 100579. CrossRef
Safety and effectiveness of ramucirumab and docetaxel: a single-arm, prospective, multicenter, non-interventional, observational, post-marketing safety study of NSCLC in Japan
Yucherng Chen, Soshi Nagaoka, Taeko Katayose, Nobuyuki Sekine
Expert Opinion on Drug Safety.2022; 21(5): 691. CrossRef
Validity of the Cancer and Aging Research Group Predictive Tool in Older Japanese Patients
Hirotaka Suto, Yumiko Inui, Atsuo Okamura
Cancers.2022; 14(9): 2075. CrossRef
Cost-effectiveness analysis of pegfilgrastim in patients with non-small cell lung cancer receiving ramucirumab plus docetaxel in Japan
Yu Kondo, Tomoya Tachi, Takayoshi Sakakibara, Jun Kato, Aki Kato, Takahito Mizuno, Yoshio Miyake, Hitomi Teramachi
Supportive Care in Cancer.2022; 30(8): 6775. CrossRef
Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 trial (ORIENT‐3)
Yuankai Shi, Lin Wu, Xinmin Yu, Puyuan Xing, Yan Wang, Jianying Zhou, Airong Wang, Jianhua Shi, Yi Hu, Ziping Wang, Guangyu An, Yong Fang, Sanyuan Sun, Caicun Zhou, Changli Wang, Feng Ye, Xingya Li, Junye Wang, Mengzhao Wang, Yunpeng Liu, Yanqiu Zhao, Yin
Cancer Communications.2022; 42(12): 1314. CrossRef
The Relevance of Docetaxel-related Febrile Neutropenia to Patient-reported Symptoms and the Quality of Life in Japanese, East Asian (Korean, Taiwanese), and Non-East Asian Patients Based on Post-hoc Analyses of Two Randomized Clinical Trials of Docetaxel
Yukie Omori, Sotaro Enatsu, Alan J.M. Brnabic, Narayan Rajan, Jin-Yuan Shih, Joo-Hang Kim, Keunchil Park, Akira Inoue
Haigan.2019; 59(7): 1140. CrossRef
Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer
Mark A. Socinski, Coleman Obasaju, David Gandara, Fred R. Hirsch, Philip Bonomi, Paul A. Bunn, Edward S. Kim, Corey J. Langer, Ronald B. Natale, Silvia Novello, Luis Paz-Ares, Maurice Pérol, Martin Reck, Suresh S. Ramalingam, Craig H. Reynolds, David R. S
Journal of Thoracic Oncology.2018; 13(2): 165. CrossRef
Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future?
Stefano Frega, Laura Bonanno, Valentina Guarneri, Pierfranco Conte, Giulia Pasello
Critical Reviews in Oncology/Hematology.2018; 128: 19. CrossRef
Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials
Chia-Jui Yen, Kei Muro, Tae-Won Kim, Masatoshi Kudo, Jin-Yuan Shih, Keun-Wook Lee, Yee Chao, Sang-We Kim, Kentaro Yamazaki, JooHyuk Sohn, Rebecca Cheng, Yawei Zhang, Polina Binder, Gu Mi, Mauro Orlando, Hyun Cheol Chung
Journal of Global Oncology.2018; (4): 1. CrossRef
Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
Makoto Nishio, Dong-Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Benjamin J. Solomon, Alice T. Shaw, Satoshi Hashigaki, Emiko Ohki, Tiziana Usari, Jolanda Paolini, Anna Polli, Keith D. Wilner, Tony Mok
Cancer Research and Treatment.2018; 50(3): 691. CrossRef
The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum
Takumi Fujiwara, Hirotsugu Kenmotsu, Tateaki Naito, Takahisa Kawamura, Nobuaki Mamesaya, Mie Kotake, Haruki Kobayashi, Shota Omori, Kazuhisa Nakashima, Kazushige Wakuda, Akira Ono, Tetsuhiko Taira, Haruyasu Murakami, Katsuhiro Omae, Keita Mori, Masahiro E
Cancer Chemotherapy and Pharmacology.2017; 79(6): 1229. CrossRef
The safety and efficacy of ramucirumab in combination with docetaxel in the treatment of lung cancer
Valérie Paulus, Virginie Avrillon, Maurice Pérol
Expert Review of Anticancer Therapy.2016; 16(11): 1119. CrossRef
Recommendations of the Austrian Working Group on Pulmonary Pathology and Oncology for predictive molecular and immunohistochemical testing in non-small cell lung cancer
Helmut H. Popper, Ulrike Gruber-Mösenbacher, Georg Hutarew, Maximilian Hochmair, Gudrun Absenger, Luka Brcic, Leonhard Müllauer, Gerhard Dekan, Ulrike Setinek, Dagmar Krenbek, Michael Vesely, Robert Pirker, Wolfgang Hilbe, Rainer Kolb, Gerald Webersinke,
memo - Magazine of European Medical Oncology.2016; 9(4): 191. CrossRef